Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET
- PMID: 15920507
- DOI: 10.1038/sj.npp.1300759
Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C]methylpiperidin-4-yl acetate ([11C]MP4A) and PET
Abstract
Donepezil hydrochloride is a potent and selective inhibitor for brain acetylcholinesterase (AChE) and is currently used worldwide for the treatment of Alzheimer's disease. Until now, there is no in vivo study on the relation between the plasma concentration and the brain AChE inhibition. The purpose of this study was to estimate in vivo plasma IC(50) of donepezil in living monkeys by measuring plasma donepezil concentration (LC/MS/MS) and brain AChE activity with positron emission tomography (PET) and N-[(11)C]methylpiperidin-4-yl acetate, which is an acetylcholine analog recently developed by us for quantifying in vivo brain AChE activity. PET scans with donepezil at two doses, 100 microg/kg (donepezil-1; N=5) or 250 microg/kg (donepezil-2; N=5), were performed using the same monkeys at 4-week intervals. Before each PET scan, baseline PET scans (N=10 in total) were performed without donepezil. The plasma donepezil concentrations 14 min after intravenous injection were proportional to the doses, 17.2+/-2.9 ng/ml (donepezil-1) and 44.0+/-5.0 ng/ml (donepezil-2), and the mean AChE inhibitions in four neocortical regions as evaluated by PET were also dose-dependent, 27% (donepezil-1) and 53% (donepezil-2). In IC(50) estimation, measured plasma donepezil concentrations were corrected for the change during PET scan. The IC(50) values (estimate+/-SE) were 42+/-9.0 (ng/ml; donepezil-1), 34+/-3.2 (donepezil-2), and 37+/-4.1 (combined data). The present method may be useful for in vivo evaluation of other AChE inhibitors and novel drugs.
Similar articles
-
Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography.Clin Neuropharmacol. 2010 Mar-Apr;33(2):74-8. doi: 10.1097/WNF.0b013e3181c71be9. Clin Neuropharmacol. 2010. PMID: 19935404 Clinical Trial.
-
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.J Clin Psychopharmacol. 2002 Dec;22(6):615-20. doi: 10.1097/00004714-200212000-00012. J Clin Psychopharmacol. 2002. PMID: 12454562 Clinical Trial.
-
Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil.Ann Pharmacother. 2004 Sep;38(9):1389-94. doi: 10.1345/aph.1D638. Epub 2004 Jul 20. Ann Pharmacother. 2004. PMID: 15266045 Clinical Trial.
-
[Pre-clinical evaluation of effects of acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: PET study in conscious monkeys].Nihon Yakurigaku Zasshi. 2004 Sep;124(3):153-61. doi: 10.1254/fpj.124.153. Nihon Yakurigaku Zasshi. 2004. PMID: 15333988 Review. Japanese.
-
PET probes for imaging brain acetylcholinesterase.J Labelled Comp Radiopharm. 2013 Mar-Apr;56(3-4):172-9. doi: 10.1002/jlcr.3002. J Labelled Comp Radiopharm. 2013. PMID: 24285323 Review.
Cited by
-
Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.Psychopharmacology (Berl). 2006 Jul;187(1):86-94. doi: 10.1007/s00213-006-0408-1. Epub 2006 Jun 1. Psychopharmacology (Berl). 2006. PMID: 16767418 Clinical Trial.
-
Use of a novel radiometric method to assess the inhibitory effect of donepezil on acetylcholinesterase activity in minimally diluted tissue samples.Br J Pharmacol. 2010 Apr;159(8):1732-42. doi: 10.1111/j.1476-5381.2010.00674.x. Br J Pharmacol. 2010. PMID: 20401964 Free PMC article.
-
PET radiopharmaceuticals for probing enzymes in the brain.Am J Nucl Med Mol Imaging. 2013 Apr 9;3(3):194-216. Print 2013. Am J Nucl Med Mol Imaging. 2013. PMID: 23638333 Free PMC article.
-
Evaluation of the sensitivity of the novel α4β2* nicotinic acetylcholine receptor PET radioligand 18F-(-)-NCFHEB to increases in synaptic acetylcholine levels in rhesus monkeys.Synapse. 2014 Nov;68(11):556-64. doi: 10.1002/syn.21767. Epub 2014 Jul 28. Synapse. 2014. PMID: 25043426 Free PMC article.
-
Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects.Drugs R D. 2021 Sep;21(3):295-304. doi: 10.1007/s40268-021-00352-5. Epub 2021 Jun 23. Drugs R D. 2021. PMID: 34164794 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources